

HIV self-testing among key populations amid COVID-19 and political conflict in Mali

Salif Diarra,¹ Ode Kanku,² Djibril Bore,³ Caterina Casalini,⁴ Tall Madani,¹ Virupax Ranebennur,⁴ Andrew Lambert,⁴ Emilie Cooper,⁴ Alain Akonde,² Diallo Youssouf,⁵ N'Tossama Diarra,³ Anthony Vautier,⁶ Jules Bashi ¹

PEC332

BACKGROUND

The Meeting Targets and Maintaining Epidemic Control (EpiC) Mali project, funded by the U.S. Agency for International Development (USAID) and the U.S. President's Emergency Plan for AIDS Relief (PEPFAR), supports the provision of HIV prevention and treatment services to key populations (KPs), who include female sex workers (FSWs) and men who have sex with men (MSM), and priority populations (PPs), who are non-KP individuals at higher risk of HIV

infection. In collaboration with the Unitaid-funded ATLAS project, KP peer navigators create demand at hot spots, offer HIV self-testing (HIVST) following risk assessment and as part of index testing, and navigate individuals to confirmatory testing and treatment sites. In March 2020, the Mali government issued a one-month curfew followed by other restrictions to control COVID-19 and political unrest until September 2020.

DESCRIPTION

In October 2019, EpiC Mali began distributing HIVST kits to hard-to-reach KPs and PPs for unassisted use to increase case detection. During COVID-19 restrictions and political conflict, HIVST was further expanded to continue reaching high-risk KP and PP individuals through contactless distribution, in compliance with COVID-19 prevention measures, but now with increased provider assistance and phone-based results follow-up.

LESSONS LEARNED

From October 2019 to September 2020, 11,579 HIVST kits were distributed. HIVST returns increased from 15 percent before COVID-19/political conflict to 72 percent post COVID-19/political conflict, particularly among KPs,

although the baseline return rate for PPs was four times higher than for KPs. The overall reactivity rate remained constant over time (KPs: 6%; PPs: 5%), but it decreased among MSM and increased among PPs. The

contribution of HIVST to total HIV case finding increased from 4 percent to 13 percent (p-value< .01; OR 3.24; CI 2.36–4.45) (Table 1).

TABLE 1. HIVST cascade, October 1, 2019–September 30, 2020

| | October 2019–March 2020 (pre-COVID-19/political conflict) | | | | | | | | April–September 2020 (during COVID-19/political conflict) | | | | | | | | October 2019–September 2020 (complete time period) | | | | | | | |
|------------|---|----------------|--------------------|----------------|--------------------|---------------------------------------|--|--|---|----------------|--------------------|----------------|--------------------|---------------------------------------|--|--|--|----------------|--------------------|----------------|--------------------|---------------------------------------|--|--|
| Population | HIVST its distributed | HIVST returned | HIVST returned (%) | HIVST reactive | HIVST reactive (%) | HIVST reactive and confirmed positive | Total HIV positive (including reactive HIVST confirmed positive) | Reactive HIVST confirmed positive contribution to total HIV positive | HIVST distributed | HIVST returned | HIVST returned (%) | HIVST reactive | HIVST reactive (%) | HIVST reactive and confirmed positive | Total HIV positive (including reactive HIVST confirmed positive) | Reactive HIVST confirmed positive contribution to total HIV positive (%) | HIVST distributed | HIVST returned | HIVST returned (%) | HIVST reactive | HIVST reactive (%) | HIVST reactive and confirmed positive | Total HIV positive (including reactive HIVST confirmed positive) | Reactive HIVST confirmed positive contribution to total HIV positive (%) |
| FSWs | 5,034 | 687 | 14% | 39 | 6% | 39 | 673 | 6% | 4,550 | 3,328 | 73% | 154 | 5% | 115 | 1,042 | 11% | 9,584 | 4,015 | 42% | 193 | 5% | 154 | 1,715 | 9% |
| MSM | 847 | 116 | 14% | 10 | 9% | 10 | 151 | 7% | 939 | 627 | 67% | 39 | 6% | 37 | 202 | 18% | 1,786 | 743 | 42% | 49 | 6% | 47 | 353 | 13% |
| PPs | 130 | 81 | 62% | 2 | 2% | 2 | 214 | 1% | 79 | 57 | 72% | 22 | 39% | 22 | 303 | 7% | 209 | 138 | 66% | 24 | 17% | 24 | 517 | 4.6% |
| Total | 6,011 | 884 | 15% | 51 | 6% | 51 | 1,265 | 4% | 5,568 | 4,012 | 72% | 215 | 5% | 174 | 1,693 | 13% | 11,579 | 4,896 | 42% | 266 | 5% | 225 | 2,958 | 8% |

CONCLUSIONS

COVID-19 and political conflict provided the impetus to shift HIVST from unassisted to assisted, resulting in a fivefold increase in return rates and a continued high reactivity rate. Decreased reactivity among MSM could be due to less-targeted HIVST kit distribution, while the high baseline return rate and high reactivity rate at follow-up among PPs requires further analysis. The increased contribution to overall case finding highlights the potential of HIVST, particularly when emergencies arise.



Training session on HIVST kit use and presentation of HIVST tools (test kit, community communication job aids, and free tool).

AUTHOR AFFILIATIONS

- ¹ FHI 360, Mali
- ² SOLTHIS-Mali
- ³ USAID/Mali
- ⁴ FHI 360, Washington, DC, USA
- ⁵ Ministry of Health/CSLSTBH, Bamako, Mali
- ⁶ SOLTHIS-Regional, Dakar, Senegal

PRESENTED AT IAS 2021 - the 11th IAS Conference on HIV Science | 18-21 JULY 2021













